The Accessible Canada Directorate within Employment and Social Development Canada (ESDC) has engaged Quorus Consulting Group to conduct the second cycle of public opinion research measuring Canadians’ awareness and experience(s) […]

Christine Thomas was only 42 when, bending to lift her newborn daughter, she fractured her spine. Diagnosed with five vertebral fractures as a result of unsuspected osteoporosis, she had no idea of the painful and transformative road she would have to travel to build stronger bones and reclaim her life.

Osteoporosis Canada advises individuals on denosumab therapy to discuss their treatment with their physician prior to delaying therapy, stopping therapy or missing a scheduled dose.   Denosumab (Prolia) has been […]

As we continue to practice physical distancing and self-isolate, it’s important to stay active to help manage your bone health and osteoporosis and to reduce your risk of breaking a […]

There are many questions for those taking osteoporosis medications and treatments including why they are being prescribed, concerns over side effects and the importance of sticking to a medication schedule. […]

Dr. Suzanne Morin has been named a member of the Canadian Institutes of Health Research (CIHR) Institute of the Musculoskeletal Health and Arthritis Advisory Board. In this capacity Dr. Morin […]

As we work to adjust to our new normal during COVID-19, now more than ever, staying fracture-free is critical for anyone with osteoporosis. Healthcare systems are over-stretched, with general recommendations […]

LONG TERM CARE Long Term Care Video Series Osteoporosis Canada, Ontario Osteoporosis Strategy, University of Waterloo and GERAS Centre for Aging Research are excited to announce the launch of four […]

Denosumab (Prolia) has been shown to reduce the risk of fracture in postmenopausal women and men ≥50 years old with osteoporosis. It has also been approved for steroid induced bone […]